6 results match your criteria: "Research and Clinical Center (MIRECC)[Affiliation]"
Adverse Outcome Following Mild Traumatic Brain Injury Is Associated with Microstructure Alterations at the Gray and White Matter Boundary.
J Clin Med
August 2023
Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Somerville, MA 02145, USA.
The gray matter/white matter (GM/WM) boundary of the brain is vulnerable to shear strain associated with mild traumatic brain injury (mTBI). It is, however, unknown whether GM/WM microstructure is associated with long-term outcomes following mTBI. The diffusion and structural MRI data of 278 participants between 18 and 65 years of age with and without military background from the Department of Defense INTRuST study were analyzed.
View Article and Find Full Text PDFWhite Matter Microstructure Is Associated with Serum Neuroactive Steroids and Psychological Functioning.
J Neurotrauma
April 2023
Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Military service members are at increased risk for mental health issues, and comorbidity with mild traumatic brain injury (mTBI) is common. Largely overlapping symptoms between conditions suggest a shared pathophysiology. The present work investigates the associations among white matter microstructure, psychological functioning, and serum neuroactive steroids that are part of the stress-response system.
View Article and Find Full Text PDFSerum Neurosteroid Levels Are Associated With Cortical Thickness in Individuals Diagnosed With Posttraumatic Stress Disorder and History of Mild Traumatic Brain Injury.
Clin EEG Neurosci
July 2020
Department of Psychiatry, Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Posttraumatic stress disorder (PTSD) co-occurring with mild traumatic brain injury (mTBI) is common in veterans. Worse clinical outcome in those with PTSD has been associated with decreased serum neurosteroid levels. Furthermore, decreased cortical thickness has been associated with both PTSD and mTBI.
View Article and Find Full Text PDFPosttraumatic Stress Disorder and Alcohol Use Disorder: A Critical Review of Pharmacologic Treatments.
Alcohol Clin Exp Res
February 2017
Center of Excellence in Substance Abuse Treatment and Education (CESATE), VA Puget Sound Health Care, Seattle, Washington.
Treatment of alcohol use disorder (AUD) is complicated by the presence of psychiatric comorbidity including posttraumatic stress disorder (PTSD). This is a critical review of the literature to date on pharmacotherapy treatments of AUD and PTSD. A systematic literature search using PubMed MESH terms for alcohol and substance use disorders, PTSD, and treatment was undertaken to identify relevant randomized controlled trials (RCTs).
View Article and Find Full Text PDFInitiation of pharmacotherapy for post-traumatic stress disorder among veterans from Iraq and Afghanistan: a dimensional, symptom cluster approach.
BJPsych Open
September 2016
, MPH PhD, VACHS, The National Center for PTSD, Department of Veterans Affairs, West Haven, CT; VACHS, The Northeast Program Evaluation Center (NEPEC), Department of Veterans Affairs, West Haven, CT; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Background: The pharmacological treatment of post-traumatic stress disorder (PTSD) is extremely challenging, as no specific agent has been developed exclusively to treat this disorder. Thus, there are growing concerns among the public, providers and consumers associated with its use as the efficacy of some agents is still in question.
Aims: We applied a dimensional and symptom cluster-based approach to better understand how the heterogeneous phenotypic presentation of PTSD may relate to the initiation of pharmacotherapy for PTSD initial episode.
Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.
Biochim Biophys Acta
August 2010
VA Mid-Atlantic Mental Illness, Research and Clinical Center (MIRECC), Durham, NC, USA.
Article Synopsis
- Allopregnanolone, a neurosteroid, has protective effects on brain health and is linked to myelination and neurogenesis, but its dysregulation may contribute to Alzheimer's disease (AD) and other neurodegenerative conditions.
- Research shows that allopregnanolone levels are significantly lower in the temporal cortex of AD patients, particularly in relation to disease stage, compared to cognitively healthy controls.
- Additionally, individuals with the APOE4 allele, which is associated with a higher risk of AD, also show reduced levels of allopregnanolone, suggesting that these neurosteroids may have implications for AD treatment and understanding its biology.